Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Datadog Inc (DDOG) Price & Performance

Abeona Therapeutics IncTrade
Datadog IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Datadog Inc — how do they compare? Abeona Therapeutics Inc trades at $7.56 (market cap $424.33M), while Datadog Inc trades at $245.5 (market cap $93.64B). The key difference: Datadog Inc is far larger — about 220.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Datadog Inc nearer its low. Which is the better fit depends on your goals.

ABEODDOG
Market Cap
$424.33M$93.64B
Sector
HealthTechnology
52-Week High
$7.45$288.15
52-Week Low
$4.17$102.62
Enterprise Value
$279.23M$89.93B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Datadog Inc

Datadog (DDOG) trades at $233.93, up 2.02% today, but remains bearish technically with resistance near $244. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.65 versus $0.583 expected, and raised full-year revenue guidance to $4.45B-$4.47B. However, the stock faces pressure from high valuations, with a P/E of 467.86, and concerns over decelerating bookings growth from a major AI customer.

Outlook is mixed: robust revenue growth and AI momentum support long-term potential, but premium valuation and near-term usage volatility pose risks. Analyst consensus is bullish with an $288.55 price target, though insider selling and technical weakness suggest cautious near-term sentiment. Investors should balance growth prospects against execution risks and market expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG